• Go to navigation
  • Go to content
Iressa.com

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca

Main navigation

  • HOME
  • About IRESSA
  • IRESSA: The story so far
  • 1st line EGFR mutation-positive advanced NSCLC
  • The IPASS study
  • Identifying EGFR mutation positive patients for NSCLC
  • Product information
  • Latest IRESSA news
  • The INTEREST study
  • Contact Us

You are here

  • HOME

  • Latest IRESSA news

Please click on the below links for the latest IRESSA news.


1 July 2009: IRESSATM (GEFITINIB) RECEIVES MARKETING AUTHORISATION FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN EUROPE

23 April 2009: IRESSATM (GEFITINIB) RECOMMENDED FOR APPROVAL FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN EUROPE






Date

Page tools

  • Print
  • Bookmark this page

Iressa Overview

  • About IRESSA

  • IRESSA: The story so far

  • IRESSA as a first line treatment for advanced NSCLC

  • The IPASS study

  • Identifying EGFR mutation positive patients for NSCLC

  • Product information

  • Latest IRESSA news

  • The INTEREST study

Legal notices

  • Terms of use
  • Privacy policy
  • © AstraZeneca 2012